Altimmune (NASDAQ:ALT) Trading 12.2% Higher – Here’s What Happened

Altimmune, Inc. (NASDAQ:ALT)’s stock price traded up 12.2% during mid-day trading on Friday . The stock traded as high as $5.74 and last traded at $5.99. 1,227,582 shares traded hands during trading, a decline of 65% from the average session volume of 3,481,969 shares. The stock had previously closed at $5.34.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ALT. Citizens Jmp lowered their price target on Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research report on Friday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Monday, October 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Altimmune in a research report on Monday, December 1st. Finally, Citigroup restated a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Altimmune has a consensus rating of “Moderate Buy” and an average target price of $16.83.

Altimmune Trading Down 1.3%

The stock has a market capitalization of $549.87 million, a PE ratio of -4.93 and a beta of -0.03. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08. The firm has a 50-day moving average price of $4.42 and a 200-day moving average price of $4.43.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.08. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. As a group, equities analysts forecast that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Altimmune

A number of hedge funds have recently modified their holdings of the stock. Deutsche Bank AG lifted its stake in Altimmune by 3.9% in the first quarter. Deutsche Bank AG now owns 79,851 shares of the company’s stock valued at $399,000 after purchasing an additional 3,026 shares during the last quarter. Nuveen LLC bought a new stake in shares of Altimmune in the first quarter valued at $1,304,000. E Fund Management Co. Ltd. lifted its position in shares of Altimmune by 20.3% during the 1st quarter. E Fund Management Co. Ltd. now owns 13,427 shares of the company’s stock valued at $67,000 after buying an additional 2,268 shares during the last quarter. Fox Run Management L.L.C. grew its stake in shares of Altimmune by 196.0% during the 1st quarter. Fox Run Management L.L.C. now owns 38,200 shares of the company’s stock worth $191,000 after acquiring an additional 25,295 shares during the period. Finally, Wellington Management Group LLP increased its holdings in Altimmune by 9.6% in the 1st quarter. Wellington Management Group LLP now owns 224,954 shares of the company’s stock worth $1,125,000 after acquiring an additional 19,721 shares during the last quarter. Institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.